| Literature DB >> 34909088 |
Siham Rouf1,2, Amine Ezzerrouqi1, Salma Benyakhlef1, Naima Abda2, Hanane Latrech1,2.
Abstract
INTRODUCTION: flexible insulin therapy (FIT) is considered as a crucial turning point in the management of type 1 diabetes. The purpose of this study was to evaluate the impact of this optimum therapeutic approach on improving metabolic control and decreasing hypoglycemic events in patients with type 1 diabetes.Entities:
Keywords: Flexible insulin therapy; control; hypoglycemic
Mesh:
Substances:
Year: 2021 PMID: 34909088 PMCID: PMC8607952 DOI: 10.11604/pamj.2021.40.100.18097
Source DB: PubMed Journal: Pan Afr Med J
Figure 1the nutritional booklet designed by our team and adapted to the Moroccan culinary traditions specifically those of the eastern region of Morocco: A) lamb or beef Moroccan tagine with vegetables (100g beef or lamb+100g vegetables): 4g carbohydrates; B) chicken Moroccan tagine with vegetables including potatoes (100g chicken+ 50g vegetables+100g potatoes): 20g carbohydrates; C) 250g Moroccan couscous (medium bowl)+ 200g vegetables: 55g carbohydrates; D) 250g berkoukech soup (the name berkoukech refers to the name of the giant couscous grains used in the soup in the berber language): 50g carbohydrates; E) chicken Moroccan tagine with olives: 10 olives: 4g carbohydrates; F) Moroccan lentil soup + fish: 250g lentils (medium bowl): 40g carbohydrates; G) pay attention to fat content of your meal
baseline characteristics of patients
| Characteristics | |
|---|---|
| Age (years), mean (SD) | 20.9 (3.7) |
| Female n (%) | 25 (67.6) |
| Duration of diabetes (years), mean (SD) | 5.7 (3.7) |
| Baseline HbA1c (%), mean (SD) | 8.4 (0.9) |
| Weight (kg), mean (SD) | 61.2 (8.1) |
| BMI (kg/m2), mean (SD) | 22.1 (2.8) |
| Total cholesterol (g/l), mean (SD) | 1.5 (0.3) |
| Triglyceride (g/l), mean (SD) | 0.8 (0.3) |
| HDL cholesterol (g/l), mean (SD) | 0.47 (0.12) |
| LDL cholesterol (g/l), mean (SD) | 0.8 (0.2) |
HDL: high-density lipoprotein; LDL: low-density lipoprotein
the outcomes in the entire group at 3, 6 and 9 months
| Outcomes | Baseline | 3 months | 6 months | 9 months | p value |
|---|---|---|---|---|---|
| Hba1c (%), mean (SD) | 8.4 (0.9) | 7.4 (1.1) | 7.6 (0.8) | 7.6 (0.7) | <0.0001 |
| BMI (kg/m2), mean (SD) | 22.1 (2.7) | 22.3 (2.9) | 22.0 (2.6) | 22.3 (2.7) | 0.02 |
| Mild hypoglycemia (episodes/3months), mean (SD) | 11.7 (2.8) | 5.6 (1.9) | 2.5 (1.4) | 1.7 (1.1) | 0.005 |
| Blood glucose (measurements per day), mean (SD) | 2.0 (0.8) | 4.5 (1.6) | 4.0 (1.6) | 4.9 (1.3) | <0.0001 |
Figure 2evolution of HbA1c in moderately controlled (HbA1c < 8% at baseline) and poorly controlled (HbA1c ≥ 8% at baseline) patients over the 9 months period of flexible insulin therapy program
the outcomes in the poorly controlled patients (HbA1c ≥ 8%) at 3, 6 and 9 months
| Outcomes | Baseline | 3 months | 6 months | 9 months | P value |
|---|---|---|---|---|---|
| Hba1c (%), mean (SD) | 9.2 (0.7) | 7.9 (1.2) | 7.9 (0.5) | 8.0 (0.6) | <0.0001 |
| BMI (kg/m2), mean (SD) | 22.4 (0.8) | 22.8 (0.9) | 22.3 (0.8) | 22.6 (0.8) | NS |
| Mild hypoglycemia (episodes/3months), mean (SD) | 10.8 (2.6) | 4.5 (1.3) | 0.9 (0.4) | 0.5 (0.3) | 0.001 |
| Blood glucose (measurements per day), mean (SD) | 2.3 (0.2) | 4.3 (0.4) | 4.0 (0.3) | 4.9 (0.3) | <0.0001 |
NS: not significant